menu
    • menu
    [{"orgOrder":0,"company":"R-Pharm","sponsor":"Vector Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.A.E","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"||Tubulin","graph1":null,"graph2":null,"graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"Infusion","sponsorNew":"R-Pharm \/ R-Pharm","highestDevelopmentStatusID":null,"companyTruncated":"R-Pharm \/ R-Pharm"}]

    Find Clinical Drug Pipeline Developments & Deals by R-Pharm

    Menu

    R-Pharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            R-Pharm

                            Russia arrow
                            Formnext Forum
                            Not Confirmed

                            R-Pharm

                            Russia arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Vector Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East

                            Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.

                            Product Name : Ixempra

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 22, 2021

                            Lead Product(s) : Ixabepilone,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Vector Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            R-Pharm

                            Russia arrow
                            Formnext Forum
                            Not Confirmed

                            R-Pharm

                            Russia arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olokizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : UCB Pharma S.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

                            Details : Olokizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 15, 2012

                            Lead Product(s) : Olokizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : UCB Pharma S.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            R-Pharm

                            Russia arrow
                            Formnext Forum
                            Not Confirmed

                            R-Pharm

                            Russia arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olokizumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Recipient : UCB Pharma S.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

                            Details : Olokizumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arthritis, Rheumatoid.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 15, 2011

                            Lead Product(s) : Olokizumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Recipient : UCB Pharma S.A

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth